- Home
- JSPR vs GHI Comparison
JSPR vs GHI Comparison
Compare JSPR & GHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | JSPR | GHI |
|---|---|---|
| Founded | 2018 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.3M | 121.3M |
| IPO Year | 2019 | 1998 |
Fundamental Metrics
Financial Performance| Metric | JSPR | GHI |
|---|---|---|
| Price | $0.62 | $5.98 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 3 |
| Target Price | ★ $15.50 | $10.50 |
| AVG Volume (30 Days) | ★ 448.0K | 37.7K |
| Earning Date | 05-12-2026 | 05-12-2026 |
| Dividend Yield | N/A | ★ 22.93% |
| EPS Growth | ★ 19.22 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $85,389,766.00 |
| Revenue This Year | N/A | $273.95 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.32 | $4.71 |
| 52 Week High | $2.69 | $10.79 |
Technical Indicators
Market Signals| Indicator | JSPR | GHI |
|---|---|---|
| Relative Strength Index (RSI) | 41.43 | 46.13 |
| Support Level | $0.55 | $6.01 |
| Resistance Level | $1.01 | $6.17 |
| Average True Range (ATR) | 0.06 | 0.19 |
| MACD | -0.01 | -0.07 |
| Stochastic Oscillator | 28.89 | 21.46 |
Price Performance
Historical ComparisonAbout JSPR Jasper Therapeutics Inc.
Jasper Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU) and asthma. The company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (KIT) receptor on mast and stem cells. The company has a single operating and reportable segment, which is the research and development of therapeutic products in the fields of chronic urticaria and asthma.
About GHI Greystone Housing Impact Investors LP Beneficial Unit Certificates representing assignments of limited partnership interests
Greystone Housing Impact Investors LP engaged in acquiring a portfolio of mortgage revenue bonds (MRBs) that are issued by state and local housing authorities to provide construction and/or permanent financing for affordable multifamily housing, seniors housing, and commercial properties. It has four reportable segments, namely Affordable Multifamily MRB Investments, Seniors and Skilled Nursing MRB Investments, MF Properties, and Market-Rate Joint Venture Investments. It generates the majority of its revenue from the Affordable Multifamily MRB Investments segment.